Characteristic | N (%) |
---|---|
Total | 58 (100) |
Pre-neoadjuvant TIL evaluation available | 43 (74.1) |
Post-neoadjuvant TIL evaluation available | 58 (100) |
Age (range 28–71 years) | |
 <50 years | 28 (48.2) |
 ≥50 years | 30 (51.7) |
Histotype | |
 Ductal | 50 (86) |
 Other | 8 (3) |
 DCIS foci | 8 (13.7) |
ER | |
 Negative | 12 (20.6) |
 Positive | 45 (77.5) |
 TNBC | 9 (15.5) |
PR | |
 Negative | 17 (29.3) |
 Positive | 40 (68.9) |
HER2 | |
 Negative | 46 (79.3) |
 Positive | 12 (20.6) |
Lymph node status | |
 Negative | 21 (36.2) |
 Positive | 37 (63.7) |
Residual tumor size | |
 <2 cm | 24 (41.3) |
  > 2 cm | 34 (58.6) |
Grade at diagnosis | |
 1 and 2 | 37 (63.7) |
 3 | 19 (32.75) |
 N/A | 2 (0.034) |
Relapse | |
 No relapse | 25 (43.1) |
 Relapse | 11 (18.9) |
 N/A | 22 (37.9) |
Neoadjuvant chemotherapy | |
 AC/taxane | 33 (56.8) |
 Other | 25 (43.1) |